Sinovac BiotechSVA 13F holders, Q1 2024 (March 31) 26 holders
1 famous investor
$25.45 avg. 13F price*
At the end of Q1 2024 , 26 institutions reported holding Sinovac Biotech Ltd. (SVA) in their 13F filings. The largest holders were Orbimed Advisors LLC ($340.0M), Vivo Capital, LLC ($76.3M) and Neumann Advisory Hong Kong Ltd ($2.0M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
Company Sinovac Biotech Ltd.
CUSIP P8696W104
Latest filing quarter Q2 2026 History Number of 13F holders
Total Exit/New Position Q1 2024 Institutions Total Value New Positions 19 $78.7M Exits 0 $0
Ownership 26 holders Portfolio Manager % of Holder's Portfolio Change Shares Value ▼ Orbimed Advisors LLC 6.24% No change 2,718,735 $340.0M Vivo Capital, LLC 6.00% New 11,800,000 $76.3M Neumann Advisory Hong Kong Ltd 1.00% No change 315,586 $2.0M State Street Corp. 0.00% New 160,875 $1.0M Renaissance Technologies 0.00% New 1,312,520 $849K Geode Capital Management, LLC 0.00% New 27,717 $179K Susquehanna International Group, LLP 0.00% New 16,430 $106K Wells Fargo & Company 0.00% New 12,750 $82K Morgan Stanley 0.00% New 6,924 $45K JPMorgan Chase & Co. 0.00% New 3,000 $19K UBS Group AG 0.00% New 2,095 $14K Group One Trading LLC 0.00% New 412 $3K Transamerica Financial Advisors, LLC 0.00% No change 2 $1K Horizon Investments, LLC 0.00% No change 52 $336 Bank of America Corp. 0.00% New 526 $0 Clearstead Advisors, LLC 0.00% New 500 $0 Navellier & Associates Inc. 0.00% Add +4.7% 14,288 $0 California Public Employees Retirement System 0.00% No change 68,732 $0 Royal Bank of Canada 0.00% New 533 $0 Assetmark, Inc. 0.00% No change 13 $0 Tower Research Capital LLC (TRC) 0.00% New 424 $0 Skandinaviska Enskilda Banken AB (publ) 0.00% New 40,000 $0 Spark Investment Management LLC 0.00% New 29,100 $0 EverSource Wealth Advisors, LLC 0.00% New 4 $0 Financial Gravity Asset Management, Inc. 0.00% Reduce -94.3% 60 $0 Atlantic Edge Private Wealth Management, LLC 0.00% New 1,000 $0
"% of holder's portfolio" is SVA's weight in each manager's 13F, not the share of Sinovac Biotech Ltd. the manager owns.